Rethinking risk-based monitoring in early phase clinical trials
Discover how risk-based monitoring strategies like tSDV can improve early phase trial oversight without compromising data integrity.
Discover how risk-based monitoring strategies like tSDV can improve early phase trial oversight without compromising data integrity.
Avance Clinical, Australia's early-phase CRO, exhibits at BIO-Europe 2026, Booth #8-24. FDA/EMA-accepted data and fast study start-up. Book a meeting.
Avance Clinical is exhibiting at AusBiotech International Conference 2026 on the Gold Coast.
Biotechs choose Avance Clinical when they need more than access to Australia – they need a CRO partner that can turn the Australian framework into a faster, more predictable early phase program.
Avance Clinical, a global full-service CRO headquartered in Australia dedicated to servicing biotech, announces the appointment of Liahna Toy as Senior Vice President & Head of Early Phase Center of Excellence, reinforcing the company’s strategic focus on accelerating high-quality early-phase trials for emerging biotech sponsors.
Phase 2 neurodegenerative trials are increasingly challenged by slow disease trajectories, heterogeneous patient populations, and blunt legacy endpoints that struggle to detect treatment-related change over typical study durations.
Helping European Biotechs Accelerate Early Phase Success With Faster Timelines, Lower Costs, and Globally Accepted Data
Avance Clinical today announced the launch of its dedicated Early Phase Center of Excellence for Biotechs
Avance Clinical has launched its Early Phase Center of Excellence for Biotechs, designed to deliver scientific rigor, innovative trial design, global regulatory insight, and operational excellence for smarter, more efficient early phase trials with significant cost savings for biotechs worldwide.